184 related articles for article (PubMed ID: 2166138)
1. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings].
Calvey TN; Chan K
Br J Clin Pharmacol; 1977 Jun; 4(3):404P. PubMed ID: 197984
[No Abstract] [Full Text] [Related]
4. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
5. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
[TBL] [Abstract][Full Text] [Related]
6. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
7. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Lundh H; Nilsson O; Rosén I
Eur Arch Psychiatry Neurol Sci; 1985; 234(6):374-7. PubMed ID: 2992990
[TBL] [Abstract][Full Text] [Related]
8. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
[TBL] [Abstract][Full Text] [Related]
10. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
11. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
12. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
13. Effects on neuromuscular function of acute chronic exposure to cholinesterase inhibitors in man and in the rat.
Roberts DV; Taylor K; Wilson A
J Physiol; 1971 Dec; 219(2):15P. PubMed ID: 4333825
[No Abstract] [Full Text] [Related]
14. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Riggs JE
Clin Neuropharmacol; 1982; 5(3):277-92. PubMed ID: 6288236
[No Abstract] [Full Text] [Related]
16. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
18. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
[No Abstract] [Full Text] [Related]
19. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
20. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
Henze T; Nenner M; Michaelis HC
J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]